Skip to content
2000
Volume 24, Issue 1
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

Parkinson’s disease (PD) is often associated with depression, which poses an additional burden for patients and their families. However, evidence regarding the optimal treatment for depression in PD remains limited, with insufficient data supporting the efficacy of most antidepressant drugs.

Methods

The primary objective of this pilot, prospective, open-label, single-arm study was to analyze the safety and tolerability of vortioxetine drops on depressive symptoms in PD patients over 16 weeks of treatment. The secondary objective was to study vortioxetine's effectiveness on depression.

Results

Sixteen out of 20 PD patients who completed the study demonstrated that the treatment was safe and well tolerated; no change in PD symptom severity, abnormality of clinical parameters, body weight, or ECG emerged. The most common side effect was nausea. Depressive symptoms rated by the Beck Depression Inventory and the Hamilton Depression Rating Scale score (HAM-D-17) showed a significant improvement at the end of the study period without a worsening of motor functions, as measured by UPDRS part III. The majority of patients also reported an improvement in depressive symptoms measured by the Patient Global Impression of Improvement scale.

Conclusion

Vortioxetine is a safe and well-tolerated therapeutic approach for depression in Parkinson’s disease. As a secondary objective, an improvement in depressive symptoms was observed. However, the study’s open-label design and small sample size limit the generalizability of the findings.

Clinical Trial Registration Number

NCT04301492.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X361647250416072053
2025-06-02
2026-02-25

  • From This Site

    /content/journals/cn/10.2174/011570159X361647250416072053
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SchapiraA.H.V. ChaudhuriK.R. JennerP. Non-motor features of parkinson disease.Nat. Rev. Neurosci.201718743545010.1038/nrn.2017.62 28592904
     [Google Scholar]
  2. TanL.C.S. Mood disorders in Parkinson’s disease.Parkinsonism Relat. Disord.201218Suppl. 1S74S7610.1016/S1353‑8020(11)70024‑4 22166461
     [Google Scholar]
  3. EserY.H. BoraH.A. KuruoğluA. Depression and Parkinson disease: Prevalence, temporal relationship, and determinants.Turk. J. Med. Sci.201747249950310.3906/sag‑1603‑101 28425238
     [Google Scholar]
  4. ReijndersJ.S.A.M. EhrtU. WeberW.E.J. AarslandD. LeentjensA.F.G. A systematic review of prevalence studies of depression in Parkinson’s disease.Mov. Disord.200823218318910.1002/mds.21803 17987654
     [Google Scholar]
  5. CongS. XiangC. ZhangS. ZhangT. WangH. CongS. Prevalence and clinical aspects of depression in Parkinson’s disease: A systematic review and meta analysis of 129 studies.Neurosci. Biobehav. Rev.202214110474910.1016/j.neubiorev.2022.104749 35750224
     [Google Scholar]
  6. HughesT.A. RossH.F. MindhamR.H.S. SpokesE.G.S. Mortality in Parkinson’s disease and its association with dementia and depression.Acta Neurol. Scand.2004110211812310.1111/j.1600‑0404.2004.00292.x 15242420
     [Google Scholar]
  7. MüllerB. AssmusJ. HerlofsonK. LarsenJ.P. TysnesO.B. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease.Parkinsonism Relat. Disord.201319111027103210.1016/j.parkreldis.2013.07.010 23916654
     [Google Scholar]
  8. StarksteinS.E. MaybergH.S. LeiguardaR. PreziosiT.J. RobinsonR.G. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease.J. Neurol. Neurosurg. Psychiatry199255537738210.1136/jnnp.55.5.377 1602311
     [Google Scholar]
  9. PontoneG.M. BakkerC.C. ChenS. MariZ. MarshL. RabinsP.V. WilliamsJ.R. BassettS.S. The longitudinal impact of depression on disability in Parkinson disease.Int. J. Geriatr. Psychiatry201631545846510.1002/gps.4350 26284815
     [Google Scholar]
  10. ShulmanL.M. TabackR.L. RabinsteinA.A. WeinerW.J. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease.Parkinsonism Relat. Disord.20028319319710.1016/S1353‑8020(01)00015‑3 12039431
     [Google Scholar]
  11. WeintraubD. MobergP.J. DudaJ.E. KatzI.R. SternM.B. Recognition and treatment of depression in Parkinson’s disease.J. Geriatr. Psychiat. Neurol.200316317818310.1177/0891988703256053 12967062
     [Google Scholar]
  12. PolitisM. NiccoliniF. Serotonin in Parkinson’s disease.Behav. Brain Res.201527713614510.1016/j.bbr.2014.07.037 25086269
     [Google Scholar]
  13. HuX. SongX. YuanY. LiE. LiuJ. LiuW. LiuY. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson’s disease.Mov. Disord.201530223824410.1002/mds.26087 25545969
     [Google Scholar]
  14. HallidayG.M. LiY.W. BlumbergsP.C. JohT.H. CottonR.G.H. HoweP.R.C. BlessingW.W. GeffenL.B. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease.Ann. Neurol.199027437338510.1002/ana.410270405 1972319
     [Google Scholar]
  15. SanchezC. AsinK.E. ArtigasF. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data.Pharmacol. Ther.2015145435710.1016/j.pharmthera.2014.07.001 25016186
     [Google Scholar]
  16. AssognaF. PellicanoC. SaviniC. MacchiusiL. PellicanoG.R. AlborghettiM. CaltagironeC. SpallettaG. PontieriF.E. Drug choices and advancements for managing depression in Parkinson’s disease.Curr. Neuropharmacol.202018427728710.2174/1570159X17666191016094857 31622207
     [Google Scholar]
  17. SchadeR.N. EtheridgeC.B. KenneyL.E. RatajskaA.M. RodriguezK. LopezF.V. GertlerJ. RayA. SantosL. HessC. BowersD. Greater apathy associated with selective serotonin reuptake inhibitor use in Parkinson’s disease.J. Geriatr. Psychiatry Neurol.2024381132210.1177/08919887241254471 38780969
     [Google Scholar]
  18. BaldwinD.S. ChronesL. FloreaI. NielsenR. NomikosG.G. PaloW. ReinesE. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.J. Psychopharmacol.201630324225210.1177/0269881116628440 26864543
     [Google Scholar]
  19. SpinaE. SantoroV. Drug interactions with vortioxetine, a new multimodal antidepressant.Riv. Psichiatr.201550521021510.1708/2040.22160 26489070
     [Google Scholar]
  20. WangY. NomikosG.G. KarimA. MunsakaM. SerenkoM. LiosatosM. HarrisS. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: Results of a thorough QT/QTc study.Clin. Pharmacol. Drug Dev.20132429830910.1002/cpdd.51 27121934
     [Google Scholar]
  21. GarcíaS.D. LosadaA.M.G. HernandoC.I. LópezC.I. BañaY.R. RedondoA.R. GonzálezP.J.M. BartoloméC.C. PainceirasF.M.J. AlvaradoI.M.C. LabandeiraC. DíazG.I. Vortioxetine improves depressive symptoms and cognition in Parkinson’s disease patients with major depression: An open-label prospective study.Brain Sci.20221211146610.3390/brainsci12111466 36358393
     [Google Scholar]
  22. StocchiF. AntoniniA. BaroneP. BellelliG. FagioliniA. StrambiF.L. SorbiS. PadovaniA. Exploring depression in Parkinson’s disease: An italian delphi consensus on phenomenology, diagnosis, and management.Neurol. Sci.20234493123313110.1007/s10072‑023‑06740‑w 37100925
     [Google Scholar]
/content/journals/cn/10.2174/011570159X361647250416072053
Loading
Vortioxetine for the Treatment of Depression in Patients with Parkinson’s Disease: A 16-week Pilot, Prospective, Open-label Safety Study
Curr. Neuropharmacol. 24, 121 (2026); https://doi.org/10.2174/011570159X361647250416072053
/content/journals/cn/10.2174/011570159X361647250416072053
/content/journals/cn/10.2174/011570159X361647250416072053
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): major depression; multimodal antidepressant; non motor symptoms; open-label; Parkinson’s disease; Vortioxetine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test